Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SLS | US
0.01
0.80%
Healthcare
Biotechnology
30/06/2024
18/10/2024
1.26
1.27
1.30
1.25
SELLAS Life Sciences Group Inc. a late-stage clinical biopharmaceutical company focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS) a cancer immunotherapeutic agent that targets Wilms tumor 1 which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co. Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai) Inc. for the development and commercialization of GFH009 a highly selective small molecule CDK9 inhibitor currently under Phase 1 clinical trials. The company is headquartered in New York New York.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
40.4%1 month
37.4%3 months
46.7%6 months
64.2%-
-
27.83
0.24
0.05
-1.71
20.84
-
-
81.06M
81.06M
-
-
-
-82.50
-888.06
17.25
12.74
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.18
Range1M
0.24
Range3M
0.39
Rel. volume
0.95
Price X volume
618.98K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MediciNova Inc | MNOV | Biotechnology | 1.81 | 88.77M | 0.28% | n/a | 0.86% |
Ovid Therapeutics Inc | OVID | Biotechnology | 1.22 | 86.59M | 4.27% | n/a | 18.40% |
CASI Pharmaceuticals Inc | CASI | Biotechnology | 5.58 | 86.27M | 2.76% | n/a | 167.26% |
Clearside Biomedical Inc | CLSD | Biotechnology | 1.15 | 85.96M | 0.00% | n/a | -168.27% |
Aclaris Therapeutics Inc | ACRS | Biotechnology | 1.19 | 84.90M | 1.71% | n/a | 2.10% |
CannaRoyalty Corp | CNNRF | Biotechnology | 4.0534 | 83.34M | 0.08% | n/a | 141.66% |
Ikena Oncology Inc. Common Stock | IKNA | Biotechnology | 1.71 | 82.52M | 0.00% | n/a | 6.36% |
PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.58 | 82.49M | -1.25% | n/a | 6.06% |
IO Biotech Inc. Common Stock | IOBT | Biotechnology | 1.24 | 81.69M | 2.48% | n/a | 2.23% |
Audentes Therapeutics Inc | BOLD | Biotechnology | 3.05 | 80.69M | 0.66% | n/a | 0.47% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.9 | 19.65M | 2.38% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.03 | 18.60M | 5.10% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.03 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 17.32% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | 22.53 | 56.33% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | 19.98% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.71 | 0.53 | Cheaper |
Ent. to Revenue | 20.84 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 27.83 | 15.55 | Expensive |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 46.68 | 72.80 | Lower Risk |
Debt to Equity | 0.24 | -1.23 | Expensive |
Debt to Assets | 0.05 | 0.25 | Cheaper |
Market Cap | 81.06M | 3.66B | Emerging |